JP2024109616A5 - - Google Patents

Download PDF

Info

Publication number
JP2024109616A5
JP2024109616A5 JP2024074184A JP2024074184A JP2024109616A5 JP 2024109616 A5 JP2024109616 A5 JP 2024109616A5 JP 2024074184 A JP2024074184 A JP 2024074184A JP 2024074184 A JP2024074184 A JP 2024074184A JP 2024109616 A5 JP2024109616 A5 JP 2024109616A5
Authority
JP
Japan
Prior art keywords
inhibitor
cxcr4
gpcrx
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024074184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024109616A (ja
JP7818648B2 (ja
Filing date
Publication date
Priority claimed from PCT/KR2018/016166 external-priority patent/WO2019124951A1/en
Application filed filed Critical
Publication of JP2024109616A publication Critical patent/JP2024109616A/ja
Publication of JP2024109616A5 publication Critical patent/JP2024109616A5/ja
Application granted granted Critical
Publication of JP7818648B2 publication Critical patent/JP7818648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024074184A 2017-12-19 2024-05-01 Gpcrヘテロマー阻害剤及びその用途 Active JP7818648B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762607876P 2017-12-19 2017-12-19
US62/607,876 2017-12-19
US201862679598P 2018-06-01 2018-06-01
US62/679,598 2018-06-01
US201862732946P 2018-09-18 2018-09-18
US62/732,946 2018-09-18
PCT/KR2018/016166 WO2019124951A1 (en) 2017-12-19 2018-12-18 Gpcr heteromer inhibitors and uses thereof
JP2020535043A JP7517986B2 (ja) 2017-12-19 2018-12-18 Gpcrヘテロマー阻害剤及びその用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020535043A Division JP7517986B2 (ja) 2017-12-19 2018-12-18 Gpcrヘテロマー阻害剤及びその用途

Publications (3)

Publication Number Publication Date
JP2024109616A JP2024109616A (ja) 2024-08-14
JP2024109616A5 true JP2024109616A5 (cg-RX-API-DMAC7.html) 2024-12-03
JP7818648B2 JP7818648B2 (ja) 2026-02-20

Family

ID=66813757

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020535043A Active JP7517986B2 (ja) 2017-12-19 2018-12-18 Gpcrヘテロマー阻害剤及びその用途
JP2024074184A Active JP7818648B2 (ja) 2017-12-19 2024-05-01 Gpcrヘテロマー阻害剤及びその用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020535043A Active JP7517986B2 (ja) 2017-12-19 2018-12-18 Gpcrヘテロマー阻害剤及びその用途

Country Status (10)

Country Link
US (3) US10709763B2 (cg-RX-API-DMAC7.html)
EP (2) EP3900712A1 (cg-RX-API-DMAC7.html)
JP (2) JP7517986B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200103018A (cg-RX-API-DMAC7.html)
CN (1) CN111741752A (cg-RX-API-DMAC7.html)
AU (1) AU2018388302B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020012075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3086337A1 (cg-RX-API-DMAC7.html)
TW (1) TWI818938B (cg-RX-API-DMAC7.html)
WO (1) WO2019124951A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
KR20220078526A (ko) * 2019-03-06 2022-06-10 인메드 파마슈티컬스 인코포레이티드 이종 시스템에서 테르페노이드 또는 칸나비노이드의 생합성을 위한 조성물 및 방법
KR20210156849A (ko) * 2019-05-17 2021-12-27 주식회사 지피씨알 Gpcr 헤테로머 저해제들 및 이의 용도
KR102268983B1 (ko) * 2019-09-11 2021-06-24 경북대학교 산학협력단 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
CN110755431B (zh) * 2019-11-08 2023-02-28 暨南大学 地氯雷他定在制备抗肝癌药物中的应用
JPWO2022025168A1 (cg-RX-API-DMAC7.html) * 2020-07-30 2022-02-03
EP4196611A1 (en) 2020-08-15 2023-06-21 Regeneron Pharmaceuticals, Inc. Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr)
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
EP4306655A4 (en) * 2021-08-04 2024-08-21 Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd PRIMER-PROBE SET, KIT AND DETECTION METHOD FOR DETECTING HUMAN HISTAMINE RECEPTOR HRH1 mRNA
CN114574580B (zh) * 2022-02-14 2022-11-29 山东大学 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
WO2023211779A1 (en) * 2022-04-25 2023-11-02 Kallyope, Inc. Treatment of headache disorders with nk3 modulators
AU2023285050A1 (en) * 2022-06-10 2025-01-23 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof
CN114891742B (zh) * 2022-06-23 2024-06-04 杭州中赢生物医疗科技有限公司 一种强杀伤性nk细胞的培养基及体外扩增方法
CN116298305B (zh) * 2023-01-03 2024-05-28 郑州大学 一种抗nt5c1a自身抗体检测方法及体外诊断试剂盒
KR20260011143A (ko) 2023-04-18 2026-01-22 칼리오페, 인크. Nk3 조정제 및 이의 용도
AU2024334309A1 (en) * 2023-08-30 2026-03-05 Josephine Cardarelli Gpcr inhibitors and uses thereof
CN119345201B (zh) * 2024-12-25 2025-03-18 中国人民解放军总医院第三医学中心 治疗tfe3基因重排性肾细胞癌的药物或药物组合物及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000538A2 (en) 1996-07-01 1998-01-08 Biosignal Inc. Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
AU3249997A (en) 1996-07-01 1998-01-21 Biosignal Inc. Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization
US6855807B1 (en) 1999-06-16 2005-02-15 New York University Heterodimeric opioid G-protein coupled receptors
US20010053848A1 (en) 2000-03-10 2001-12-20 Patel Yogesh C. Hetero-oligomeric G protein-coupled receptors as novel drug targets
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
EP1625159B1 (en) 2003-05-20 2011-03-02 The University Court Of The University Of Glasgow Materials and methods relating to g-protein coupled receptor oligomers
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
CA2640087A1 (en) * 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
US9212226B2 (en) * 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2010002468A1 (en) 2008-07-01 2010-01-07 The Trustees Of Columbia University In The City Of New York A functional complementation assay for defined gpcr oligomers
FR2949156B1 (fr) 2009-08-13 2016-04-15 Cis-Bio Int Methode de determination de la liaison d'un compose donne a un recepteur membranaire
WO2011091435A2 (en) 2010-01-25 2011-07-28 Mount Sinai School Of Medicine Methods of treating liver disease
JP2011168567A (ja) * 2010-02-22 2011-09-01 Kyoto Univ 再発癌の予防または治療用医薬
KR101029972B1 (ko) 2010-06-18 2011-04-20 서울대학교산학협력단 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법
WO2012047339A2 (en) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
US9267934B2 (en) * 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
MX371455B (es) * 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
WO2015095973A1 (en) 2013-12-23 2015-07-02 Université de Montréal Systems and methods for the monitoring of protein complex formation in cells
DK3242685T3 (da) * 2015-01-09 2022-07-25 Adalta Ltd Cxcr4-bindende molekyler
WO2017020128A1 (en) * 2015-08-03 2017-02-09 Université de Montréal Markers for acute myeloid leukemias with core binding factor rearrangements and other genetic subtypes and uses thereof
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2021507925A5 (cg-RX-API-DMAC7.html)
Magnaghi et al. Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury
Nakagawa et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors
Cheng et al. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
Pernis et al. Interleukin 4 signals through two related pathways.
MX2013010581A (es) Receptor del factor de crecimiento de fibroblastos (fgfr) y ligandos del mismo como biomarcadores para cancer de mama en sujetos hr positivos.
JP2009092508A (ja) リウマチ治療剤の効果の予測方法
ES2663843T3 (es) Utilización de la proteína olfactomedina-4 (OLFM4) en el diagnóstico del cáncer colorrectal
US20150361504A1 (en) Biomarker for predicting response of cll to treatment with a btk inhibitor
McLeskey et al. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Sabah et al. The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining
Sequeira et al. The oral and skin pathergy test
Lee et al. Genetic analysis of ovarian microcystic stromal tumor
KR20230147136A (ko) Raf 억제제와 mek 억제제의 조합
Hornick et al. The significance of KIT (CD117) in gastrointestinal stromal tumors
Koyama et al. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment
Kang et al. Extragastrointestinal stromal tumor presenting as a scrotal mass: an unusual case
US10426777B2 (en) Methods used to treat cancer
Potti et al. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma
JP2008515459A (ja) オートクライン成長因子受容体および方法
Rolfes et al. 421TiP OPTImaL: Optimisation of treatment for patients with low stage triple-negative breast cancer with high stromal tumor-infiltrating lymphocytes
Khrais et al. Primary cutaneous anaplastic large cell lymphoma with gastric metastasis
Zhang et al. 1422P Identification and validation of novel microenvironment-based immune molecular subgroups of esophageal squamous-cell carcinoma
Ananthaswamy et al. Correlation between Ha-ras gene amplification and spontaneous metastasis in NIH 3T3 cells transfected with genomic DNA from human skin cancers
EP4715383A1 (en) Test strip for testing analyte in sample